Travere Therapeutics (TVTX) News Today $17.14 -0.36 (-2.06%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Travere Therapeutics, Inc. (NASDAQ:TVTX) Position Trimmed by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd reduced its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 70.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 28,217 shares of the company's stock after selling 67,065 shares during the quaDecember 17 at 4:01 AM | marketbeat.comFmr LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Fmr LLC increased its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 27.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 147,416 shares of the company's stock after purchasing an additional 31,December 15 at 3:22 AM | marketbeat.comTwo Sigma Advisers LP Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Two Sigma Advisers LP lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 30.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 720,400 shares of the company's stock afteDecember 10, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Point72 Asia Singapore Pte. Ltd.Point72 Asia Singapore Pte. Ltd. decreased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 88.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,037 shares of the company's stock after sellingDecember 8, 2024 | marketbeat.comBrokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $22.62December 8, 2024 | americanbankingnews.comJacobs Levy Equity Management Inc. Has $22.25 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jacobs Levy Equity Management Inc. cut its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 15.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,590,377 shares of the company's stock after selling 299,467 shaDecember 5, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven haveDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Parkman Healthcare Partners LLC boosted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,086,067 shares of the company's stock after purchasing an additional 116,175 shares during theDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Sells 72,183 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)HighVista Strategies LLC reduced its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 32.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 147,233 shares of the company's stock aDecember 3, 2024 | marketbeat.comBellevue Group AG Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Bellevue Group AG purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 31,000 shares of the company's stock, valued at approximatDecember 2, 2024 | marketbeat.comWalleye Capital LLC Acquires 201,282 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Walleye Capital LLC increased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 70.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 488,453 shares of the company's stock after purchasing an additional 201,282 shDecember 1, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 37.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 843,300 sharesNovember 29, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $221,247.00 in StockNovember 26, 2024 | insidertrades.comTravere Therapeutics to Present at Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Purchases 52,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Connor Clark & Lunn Investment Management Ltd. grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 11.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 525,381 shares of the company's stockNovember 23, 2024 | marketbeat.comTravere Therapeutics (TVTX) Gets a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comOppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)Oppenheimer & Co. Inc. bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 48,139 shares of the company's stock, valued at approximatelNovember 21, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 18, 2024 | prnewswire.comMHRA approves Travere’s sparsentan to treat adults with primary IgANNovember 18, 2024 | markets.businessinsider.comLos Angeles Capital Management LLC Sells 56,866 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Los Angeles Capital Management LLC lowered its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 67.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 27,951 shares of the company's stock after selling 56,866 shares during the pNovember 18, 2024 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockPiper Sandler increased their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday.November 14, 2024 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 13, 2024 | globenewswire.com3 Under-the-Radar Healthcare Companies (TVTX)While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.November 11, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 10, 2024 | prnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eleven have giveNovember 10, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Hits New 12-Month High - Here's What HappenedNovember 8, 2024 | marketbeat.comTravere Therapeutics Announces Pricing of Public Offering of Common StockNovember 7, 2024 | globenewswire.comTravere Therapeutics Announces Proposed Public Offering of Common StockNovember 7, 2024 | globenewswire.comStifel Nicolaus Remains a Hold on Travere Therapeutics (TVTX)November 5, 2024 | markets.businessinsider.comTravere Therapeutics to Present at Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Emerald Advisers LLCEmerald Advisers LLC boosted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 19.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,960,659 shares of the company's stock after purchaNovember 3, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 2, 2024 | prnewswire.comTravere Therapeutics (NASDAQ:TVTX) Given New $27.00 Price Target at ScotiabankScotiabank raised their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a research report on Friday.November 1, 2024 | marketbeat.comTravere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...November 1, 2024 | finance.yahoo.comTravere Therapeutics Boosts Sales with FILSPARI ApprovalNovember 1, 2024 | markets.businessinsider.comTravere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to ExpectOctober 31, 2024 | finance.yahoo.comTravere Therapeutics Reports Third Quarter 2024 Financial ResultsOctober 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Promising Filspari Efficacy in Treating IgAN and FSGSOctober 29, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Travere Therapeutics (TVTX)October 29, 2024 | markets.businessinsider.comSemanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX)Semanteon Capital Management LP acquired a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 36,699 shares of the company's stock, valuedOctober 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $19.23 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Assenagon Asset Management S.A. decreased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 37.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,374,522 shares of the company's stock after selliOctober 27, 2024 | marketbeat.comTravere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024October 26, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXOctober 25, 2024 | prnewswire.comTravere Therapeutics (TVTX) Set to Announce Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638084)October 24, 2024 | marketbeat.comWells Fargo Upgrades Travere Therapeutics (TVTX)October 22, 2024 | msn.comTravere Therapeutics to Report Third Quarter 2024 Financial ResultsOctober 21, 2024 | globenewswire.comWells Fargo upgrades Travere Therapeutics to Overweight on further upsideOctober 21, 2024 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up - Time to Buy?Travere Therapeutics (NASDAQ:TVTX) Shares Gap Up - Should You Buy?October 21, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & CompanyWells Fargo & Company raised shares of Travere Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $9.00 to $27.00 in a research report on Monday.October 21, 2024 | marketbeat.comState Street Corp's Strategic Reduction in Travere Therapeutics HoldingsOctober 18, 2024 | finance.yahoo.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼1.100.69▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼25▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Today Viking Therapeutics News Today BridgeBio Pharma News Today Crinetics Pharmaceuticals News Today Krystal Biotech News Today Arcellx News Today ADMA Biologics News Today Ultragenyx Pharmaceutical News Today Apellis Pharmaceuticals News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
